Isatuximab Added to RVd Boosts Response in New Myeloma

The addition of the anti-CD38 antibody improved minimal residual disease rates at the end of induction, a marker for better outcomes following autologous stem cell transplant.
Medscape Medical News

source https://www.medscape.com/viewarticle/964650?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension